Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03186378 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.
A Phase 2 study, sponsored by Verrica Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT03186378: Completed Phase 2 study, sponsored by Verrica Pharmaceuticals.
NCT03186378 is a Phase 2 study that has completed, run by Verrica Pharmaceuticals. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03186378, a Phase 2 study, has completed, sponsored by Verrica Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution \[0.7% (w/v) cantharidin\] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older. Treatment will continue over the course of 3 additional 21 day intervals allowing for further evaluation of safety, efficacy and impact on quality of life.
Primary Outcome
The primary objective is to determine any potential systemic exposure from a single 24-hour dermal application of VP-102 topical film-forming solution when applied to molluscum contagiosum (molluscum) lesions on pediatric subjects 2 years old and older.
Interventions
- COMBINATION_PRODUCT VP-102 with applicator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2018-06-25 |
| Phase | Phase 2 |
What the finished NCT03186378 record still lists
NCT03186378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which VP-102 with applicator is the first listed.
NCT03186378 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03186378 about?
NCT03186378 is a clinical study titled "Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.". The primary objective of the study is to determine the presence or absence of systemic cantharidin exposure from a single 24-hour dermal application of VP-102 topical film-forming solution \[0.7% (w/v) cantharidin\] (VP-102) when applied to molluscum contagiosum (molluscum) lesions on pediatric subj...
What is the current status of trial NCT03186378?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2017-06-08. Estimated completion is 2018-06-25.
What interventions are being tested in trial NCT03186378?
The interventions under investigation include: VP-102 with applicator (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03186378?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03186378's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI